TY - JOUR
T1 - Household transmission of influenza (H1N1-2009) in Japan
T2 - Age-specificity and reduction of household transmission risk by Zanamivir treatment
AU - Nishiura, H.
AU - Oshitani, H.
PY - 2011/4
Y1 - 2011/4
N2 - This study investigated household transmission data for influenza (H1N1-2009) in Japan in order to quantify the age-specific risk of infection and estimate the impact of antiviral treatment on the risk of household transmission. Among a total of 1547 households, involving 4609 household contacts, the secondary attack ratio (SAR) was estimated to be 11.4%. School children aged 5 - 18 years dominated the index cases. Age-specific infectiousness and susceptibility were highest among 0 - 4-year olds, with SAR estimated at 19.4% and 29.6%, respectively. Zanamivir treatment within 24 and 24 - 48 h of illness onset in index cases, respectively, reduced the risk of household transmission to 0.57 (95% CI 0.44, 0.73) and 0.58 (95% CI 0.38, 0.86) times that among those receiving the same treatment at > 48 h and those not receiving treatment. The preventive performance of antiviral treatment and prophylaxis should be further examined in randomized controlled trials.
AB - This study investigated household transmission data for influenza (H1N1-2009) in Japan in order to quantify the age-specific risk of infection and estimate the impact of antiviral treatment on the risk of household transmission. Among a total of 1547 households, involving 4609 household contacts, the secondary attack ratio (SAR) was estimated to be 11.4%. School children aged 5 - 18 years dominated the index cases. Age-specific infectiousness and susceptibility were highest among 0 - 4-year olds, with SAR estimated at 19.4% and 29.6%, respectively. Zanamivir treatment within 24 and 24 - 48 h of illness onset in index cases, respectively, reduced the risk of household transmission to 0.57 (95% CI 0.44, 0.73) and 0.58 (95% CI 0.38, 0.86) times that among those receiving the same treatment at > 48 h and those not receiving treatment. The preventive performance of antiviral treatment and prophylaxis should be further examined in randomized controlled trials.
KW - Antiviral drugs
KW - Epidemiology
KW - H1N1-2009
KW - Influenza
KW - Neuraminidase inhibitors
KW - Oseltamivir
KW - Pandemic
KW - Prophylaxis
KW - Zanamivir
UR - http://www.scopus.com/inward/record.url?scp=79955673057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955673057&partnerID=8YFLogxK
U2 - 10.1177/147323001103900231
DO - 10.1177/147323001103900231
M3 - Article
C2 - 21672367
AN - SCOPUS:79955673057
SN - 0300-0605
VL - 39
SP - 619
EP - 628
JO - Journal of International Medical Research
JF - Journal of International Medical Research
IS - 2
ER -